Support for the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia from exome sequencing in multiplex families.

IMPORTANCE Schizophrenia is a complex genetic disorder demonstrating considerable heritability. Genetic studies have implicated many different genes and pathways, but much of the genetic liability remains unaccounted for. Investigation of genetic forms of schizophrenia will lead to a better understanding of the underlying molecular pathways, which will then enable targeted approaches for disease prevention and treatment. OBJECTIVE To identify new genetic factors strongly predisposing to schizophrenia in families with multiple affected individuals with schizophrenia. DESIGN We performed genome-wide array comparative genomic hybridization, linkage analysis, and exome sequencing in multiplex families with schizophrenia. SETTING Probands and their family members were recruited from academic medical centers. PARTICIPANTS We intended to identify rare disease-causing mutations in 5 large families where schizophrenia transmission appears consistent with single-gene inheritance. INTERVENTION Array comparative genomic hybridization was used to identify copy number variants, while exome sequencing was used to identify variants shared in all affected individuals and linkage analysis was used to further filter shared variants of interest. Analysis of select variants was performed in cultured cells to assess their functional consequences. MAIN OUTCOME MEASURES Rare inherited disease-related genetic mutations. RESULTS No segregating rare copy number variants were detected by array comparative genomic hybridization. However, in all 5 families, exome sequencing detected rare protein-altering variants in 1 of 3 genes associated with the N -methyl-D-aspartate (NMDA) receptor. One pedigree shared a missense and frameshift substitution of GRM5, encoding the metabotropic glutamate receptor subtype 5 (mGluR5), which is coupled to the NMDA receptor and potentiates its signaling; the frameshift disrupts binding to the scaffolding protein tamalin and increases mGluR5 internalization. Another pedigree transmitted a missense substitution in PPEF2, encoding a calmodulin-binding protein phosphatase, which we show influences mGluR5 levels. Three pedigrees demonstrated different missense substitutions within LRP1B, encoding a low-density lipoprotein receptor-related protein tied to both the NMDA receptor and located in a chromosome 2q22 region previously strongly linked to schizophrenia. CONCLUSIONS AND RELEVANCE Exome sequencing of multiplex pedigrees uncovers new genes associated with risk for developing schizophrenia and suggests potential novel therapeutic targets.

[1]  R. Sweet,et al.  Genetics of psychosis in Alzheimer's disease: a review. , 2010, Journal of Alzheimer's disease : JAD.

[2]  Thomas W. Mühleisen,et al.  Large recurrent microdeletions associated with schizophrenia , 2008, Nature.

[3]  K. Kanuma,et al.  Recent patents on positive allosteric modulators of the metabotropic glutamate 5 receptor as a potential treatment for schizophrenia. , 2010, Recent patents on CNS drug discovery.

[4]  Janet B W Williams,et al.  Diagnostic and Statistical Manual of Mental Disorders , 2013 .

[5]  D. Blackwood,et al.  The genomic organisation of the metabotropic glutamate receptor subtype 5 gene, and its association with schizophrenia , 2001, Molecular Psychiatry.

[6]  Pablo V Gejman,et al.  Genetics of schizophrenia: new findings and challenges. , 2011, Annual review of genomics and human genetics.

[7]  M. Constantine‐Paton,et al.  Receptor compartmentalization and trafficking at glutamate synapses: a developmental proposal , 2004, Trends in Neurosciences.

[8]  M. Geyer,et al.  Assessment of a prepulse inhibition deficit in a mutant mouse lacking mGlu5 receptors , 2004, Molecular Psychiatry.

[9]  E. Walker,et al.  Diagnostic and Statistical Manual of Mental Disorders , 2013 .

[10]  G. Bu,et al.  LRP in Amyloid‐β Production and Metabolism , 2006 .

[11]  E. Eichler,et al.  Phenotypic variability and genetic susceptibility to genomic disorders. , 2010, Human molecular genetics.

[12]  S. Levy,et al.  Exome sequencing supports a de novo mutational paradigm for schizophrenia , 2011, Nature Genetics.

[13]  Martin S. Taylor,et al.  Disruption of two novel genes by a translocation co-segregating with schizophrenia. , 2000, Human molecular genetics.

[14]  D. Rujescu,et al.  Homer-1 polymorphisms are associated with psychopathology and response to treatment in schizophrenic patients. , 2011, Journal of psychiatric research.

[15]  A. Andreeva,et al.  Protein Ser/Thr phosphatases PPEF interact with calmodulin. , 2002, Biochemical and biophysical research communications.

[16]  Y. Pawitan,et al.  A new paradigm emerges from the study of de novo mutations in the context of neurodevelopmental disease , 2013, Molecular Psychiatry.

[17]  Joseph A. Gogos,et al.  Strong association of de novo copy number mutations with sporadic schizophrenia , 2008, Nature Genetics.

[18]  Liam Scott,et al.  Role of Thalamic Projection in NMDA Receptor-Induced Disruption of Cortical Slow Oscillation and Short-Term Plasticity , 2011, Front. Psychiatry.

[19]  Vance P Lemmon,et al.  Kinase/phosphatase overexpression reveals pathways regulating hippocampal neuron morphology , 2010, Molecular systems biology.

[20]  Serafim Batzoglou,et al.  Identifying a High Fraction of the Human Genome to be under Selective Constraint Using GERP++ , 2010, PLoS Comput. Biol..

[21]  Anders D. Børglum,et al.  Genome-wide association study identifies five new schizophrenia loci , 2011, Nature Genetics.

[22]  S. Nakanishi,et al.  Tamalin Is a Scaffold Protein That Interacts with Multiple Neuronal Proteins in Distinct Modes of Protein-Protein Association* , 2003, The Journal of Biological Chemistry.

[23]  A. Singleton,et al.  Rare Structural Variants Disrupt Multiple Genes in Neurodevelopmental Pathways in Schizophrenia , 2008, Science.

[24]  B. Sarg,et al.  LRP1b shows restricted expression in human tissues and binds to several extracellular ligands, including fibrinogen and apoE – carrying lipoproteins , 2011, Atherosclerosis.

[25]  M. Gill,et al.  Replicated genetic evidence supports a role for HOMER2 in schizophrenia , 2010, Neuroscience Letters.

[26]  P. Visscher,et al.  Rare chromosomal deletions and duplications increase risk of schizophrenia , 2008, Nature.

[27]  Eran Halperin,et al.  A model based approach for analysis of spatial structure in genetic data , 2013 .

[28]  G. Bu,et al.  LRP in amyloid-beta production and metabolism. , 2006, Annals of the New York Academy of Sciences.

[29]  P. McKenna,et al.  Expression of the human excitatory amino acid transporter 2 and metabotropic glutamate receptors 3 and 5 in the prefrontal cortex from normal individuals and patients with schizophrenia. , 1998, Brain research. Molecular brain research.

[30]  Ronak K. Kapadia,et al.  Clinically detectable copy number variations in a Canadian catchment population of schizophrenia. , 2010, Journal of psychiatric research.

[31]  N. Uranova,et al.  Ultrastructural alterations in hippocampal mossy fiber synapses in schizophrenia: A postmortem morphometric study , 2005, Synapse.

[32]  Gregory M. Cooper,et al.  A Copy Number Variation Morbidity Map of Developmental Delay , 2011, Nature Genetics.

[33]  S. Lok,et al.  Increased exonic de novo mutation rate in individuals with schizophrenia , 2011, Nature Genetics.

[34]  Pall I. Olason,et al.  Common variants conferring risk of schizophrenia , 2009, Nature.

[35]  Daniel L. Koller,et al.  Convergent functional genomics of schizophrenia: from comprehensive understanding to genetic risk prediction , 2012, Molecular Psychiatry.

[36]  K. Roche,et al.  Subunit-Specific Regulation of NMDA Receptor Endocytosis , 2004, The Journal of Neuroscience.

[37]  J. Coyle,et al.  PAGES_DCNS 46_5.qxd:DCNS#45 , 2010 .

[38]  Stephen W Scherer,et al.  Copy number variations in schizophrenia: critical review and new perspectives on concepts of genetics and disease. , 2010, The American journal of psychiatry.

[39]  Carlos S. Moreno,et al.  Relative Burden of Large CNVs on a Range of Neurodevelopmental Phenotypes , 2011, PLoS genetics.

[40]  J. Nurnberger,et al.  Diagnostic interview for genetic studies. Rationale, unique features, and training. NIMH Genetics Initiative. , 1994, Archives of general psychiatry.

[41]  D. Clair,et al.  Association within a family of a balanced autosomal translocation with major mental illness , 1990, The Lancet.

[42]  S Purcell,et al.  De novo CNV analysis implicates specific abnormalities of postsynaptic signalling complexes in the pathogenesis of schizophrenia , 2011, Molecular Psychiatry.

[43]  T. Matise,et al.  Genome-wide search for schizophrenia susceptibility loci: the NIMH Genetics Initiative and Millennium Consortium. , 1998, American journal of medical genetics.

[44]  M. Tsuang Genotypes, Phenotypes, and the Brain , 1993, British Journal of Psychiatry.

[45]  R. Hammer,et al.  Normal Development and Fertility of Knockout Mice Lacking the Tumor Suppressor Gene LRP1b Suggest Functional Compensation by LRP1 , 2004, Molecular and Cellular Biology.

[46]  Yonghe Li,et al.  The Putative Tumor Suppressor LRP1B, a Novel Member of the Low Density Lipoprotein (LDL) Receptor Family, Exhibits Both Overlapping and Distinct Properties with the LDL Receptor-related Protein* , 2001, The Journal of Biological Chemistry.

[47]  W. Danysz,et al.  The role of group I metabotropic glutamate receptors in schizophrenia , 2007, Amino Acids.

[48]  E M Wijsman,et al.  Meta-analysis of 32 genome-wide linkage studies of schizophrenia , 2009, Molecular Psychiatry.

[49]  Susanne Walitza,et al.  Genome-wide copy number variation study associates metabotropic glutamate receptor gene networks with attention deficit hyperactivity disorder , 2011, Nature Genetics.